Riluzole in psychiatry: a systematic review of the literature

Bibliography

• Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006;59(11):1006-20
   PubMed Web of Science ®Google Scholar
• Schloesser RJ, Huang J, Klein PS, et al. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008;33(1):110-33
   PubMed Web of Science ®Google Scholar
• Newberg AR, Catapano LA, Zarate CA, et al. Neurobiology of bipolar disorder. Expert Rev Neurother 2008;8(1):93-110
   PubMedGoogle Scholar
• Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000;48(8):813-29
   PubMed Web of Science ®Google Scholar
• Heurteaux C, Laigle C, Blondeau N, et al. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006;137(1):241-51
   PubMed Web of Science ®Google Scholar
• Ates O, Cayli SR, Gurses I, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 2007;14(7):658-65
   PubMed Web of Science ®Google Scholar
• Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001;94(2 Suppl):245-56
   PubMed Web of Science ®Google Scholar
• Benazzouz A, Boraud T, Dubedat P, et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995;284(3):299-307
   PubMed Web of Science ®Google Scholar
• Medico M, Nicosia A, Grech M, et al. Riluzole restores motor activity in rats with post-traumatic peripheral neuropathy. Neurosci Lett 2004;358(1):37-40
   PubMed Web of Science ®Google Scholar
• Ruel J, Wang J, Pujol R, et al. Neuroprotective effect of riluzole in acute noise-induced hearing loss. Neuroreport 2005;16(10):1087-90
   PubMed Web of Science ®Google Scholar
• Peyclit A, Keita H, Juvin P, et al. Effects of riluzole on N-methyl-D-aspartate-induced tyrosine phosphorylation in the rat hippocampus. Brain Res 2001;903(1-2):222-5
   PubMed Web of Science ®Google Scholar
• Dagci T, Yilmaz O, Taskiran D, et al. Neuroprotective agents: is effective on toxicity in glial cells? Cell Mol Neurobiol 2007;27(2):171-7
   PubMed Web of Science ®Google Scholar
• Bensimon GL, Lacomblez, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585-91
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347(9013):1425-31
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62(3):262-72
   PubMed Web of Science ®Google Scholar
• Seppi K, Peralta C, Diem-Zangerl A, et al. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 2006;13(10):1146-8
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8(4):271-6
   PubMed Web of Science ®Google Scholar
• Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002;8(6):532-3
   PubMed Web of Science ®Google Scholar
• Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250(3):473-6
   PubMed Web of Science ®Google Scholar
• Lingamaneni R, Hemmings HC Jr. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci Lett 1999;276(2):127-30
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16(3):675-86
   PubMed Web of Science ®Google Scholar
• Fumagalli E, Funicello M, Rauen T, et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol 2008;578(2-3):171-6
   PubMed Web of Science ®Google Scholar
• Azbill RD, Mu X, Springer JE. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000;871(2):175-80
   PubMed Web of Science ®Google Scholar
• Dunlop J, Beal McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003;23:1688-96
   PubMed Web of Science ®Google Scholar
• Frizzo ME, Dall'Onder LP, Dalcin KB, et al. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004;24(1):123-8
   PubMed Web of Science ®Google Scholar
• Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007;32(4):793-802
   PubMed Web of Science ®Google Scholar
• Debono MW, Le Guern J, Canton T, et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235(2-3):283-9
   PubMed Web of Science ®Google Scholar
• Jehle T, Bauer J, Blauth E, et al. Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 2000;130(6):1227-34
   PubMed Web of Science ®Google Scholar
• Warner-Schmidt JL, Duman R. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008;8:14-9
   PubMed Web of Science ®Google Scholar
• Iga J, Ueno S, Yamauchi K, et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(3):658-63
   PubMed Web of Science ®Google Scholar
• Heine VM, Zareno J, Maslam S, et al. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurol 2005;21:1301-14
   Google Scholar
• Warner-Schmidt JL, Duman R. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007;104:4647-52
   PubMed Web of Science ®Google Scholar
• Yoo MH, Yoon YH, Chung H, et al. Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole. Invest Ophthalmol Vis Sci 2007;48(12):5671-6
   PubMed Web of Science ®Google Scholar
• Mizuta I, Ohta M, Ohta K, et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001;310(2-3):117-20
   PubMed Web of Science ®Google Scholar
• Katoh-Semba R, Asano T, Ueda H, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002;16(10):1328-30
   PubMed Web of Science ®Google Scholar
• Benavides J, Camelin JC, Mitrani N, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission – II. Biochemical properties. Neuropharmacology 1985;24(11):1085-92
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3(1):23-9
   PubMed Web of Science ®Google Scholar
• Banasr M, Chowdhury G, Duman R, et al. Riluzole blocks stress-related effects on behavior and enhances glutamate/glutamine cycle flux. in Neuropsychopharmacology 2006
   Google Scholar
• Singh J, Zarate CA Jr, Krystal AD. Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology (Berl) 2004;173(1-2):227-8
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161(1):171-4
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57(4):430-2
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61(6):822-5
   PubMed Web of Science ®Google Scholar
• Lourenco Da Silva A, Hoffmann A, Dietrich MO, et al. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003;48(1):27-30
   PubMed Web of Science ®Google Scholar
• Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8 Pt 2):8-11
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006;51(13):823-35
   PubMed Web of Science ®Google Scholar
• Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry 1993;150(8):1257-8
   PubMed Web of Science ®Google Scholar
• Coryell W, Endicott J, Andreasen NC, et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988;145(3):293-300
   PubMed Web of Science ®Google Scholar
• Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 2002;16(1):4-13
   PubMed Web of Science ®Google Scholar
• Fawcett J. Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry 1992;53(Suppl):9-13
   PubMed Web of Science ®Google Scholar
• He Y, Benz A, Fu T, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology 2002;42(2):199-209
   PubMed Web of Science ®Google Scholar
• Stutzmann JM, Cintrat P, Laduron PM, et al. Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats. Psychopharmacology (Berl) 1989;99(4):515-9
   PubMed Web of Science ®Google Scholar
• Munro G, Erichsen HK, Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology 2007;53(5):609-18
   PubMed Web of Science ®Google Scholar
• Kniest A, Wiesenberg C, Weber B, et al. The glutamate antagonist riluzole and its effects upon basal and stress-induced activity of the human hypothalamus-pituitary-adrenocortical system in elderly subjects. Neuropsychobiology 2001;43(2):91-5
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Price RB, Mao X, et al. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 2008;63(9):891-8
   PubMed Web of Science ®Google Scholar
• Coric, V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003;167(2):219-20
   PubMed Web of Science ®Google Scholar
• Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58(5):424-8
   PubMed Web of Science ®Google Scholar
• Grant P, Lougee L, Hirschtritt M, et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007;17(6):761-7
   PubMed Web of Science ®Google Scholar
• Egashira N, Okuno R, Harada S, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008
   Google Scholar
• Sasso DA, Kalanithi PS, Trueblood KV, et al. Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol 2006;26(6):685-7
   PubMed Web of Science ®Google Scholar
• Coric V, Kelmendi B, Pittenger C, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. J Clin Psychiatry 2007;68(1):170-1
   PubMed Web of Science ®Google Scholar
• Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry 2005;66(11):1492-3
   PubMed Web of Science ®Google Scholar
• Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006;3(1):69-81
   PubMedGoogle Scholar
• Ciraulo DA, Sarid-Segal O, Knapp CM, et al. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction 2005;100(Suppl 1):12-22
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;1:CD001447
   PubMedGoogle Scholar
• Groeneveld GJ, Van Kan HJ, Kalmijn S, et al. Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology 2003;61(8):1141-3
   PubMed Web of Science ®Google Scholar
• Sorenson, EJ. An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology 2006;67(12):2260-1
   PubMed Web of Science ®Google Scholar
• Pittenger C, Naungayan C, Kendell SF, et al. Visual hallucinations from the addition of riluzole to memantine and bupropion. J Clin Psychopharmacol 2006;26(2):218-20
   PubMed Web of Science ®Google Scholar
• Remy AJ, Camu W, Ramos J, et al. Acute hepatitis after riluzole administration. J Hepatol 1999;30(3):527-30
   PubMed Web of Science ®Google Scholar
• Rodrigo L, Moreno M, Calleja S, et al. Riluzole-induced acute pancreatitis. Am J Gastroenterol 2001;96(7):2268-9
   PubMed Web of Science ®Google Scholar
• Cassiman D, Thomeer M, Verbeken E, et al. Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. Neurology 2003;61(8):1150-1
   PubMed Web of Science ®Google Scholar
• Woolf A, Carstairs SD, Tanen DA. Riluzole-induced methemoglobinemia. Ann Emerg Med 2004;43(2):294
   PubMed Web of Science ®Google Scholar
• Viallon A, Page Y, Bertrand JC. Methemoglobinemia due to riluzole. N Engl J Med 2000;343(9):665-6
   PubMed Web of Science ®Google Scholar
• Lipp A, Tank J, Stoffels M, et al. Riluzole and blood pressure in multiple system atrophy. Clin Auton Res 2003;13(4):271-4
   PubMed Web of Science ®Google Scholar
• Scelsa SN, Khan I. Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur Neurol 2000;43(4):224-7
   PubMed Web of Science ®Google Scholar
• Wagner ML, Landis BE. Riluzole: a new agent for amyotrophic lateral sclerosis. Ann Pharmacother 1997;31(6):738-44
   PubMed Web of Science ®Google Scholar
• North WA, Khan AM, Yamase HT, et al. Reversible granulocytopenia in association with riluzole therapy. Ann Pharmacother 2000;34(3):322-4
   PubMed Web of Science ®Google Scholar
• Wokke J. Riluzole. Lancet 1996;348(9030):795-9
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, van Kan HJ, Torano JS, et al. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. J Neurol Sci 2001;191(1-2):121-5
   PubMed Web of Science ®Google Scholar
• Sanderink GJ, Bournique B, Stevens J, et al. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997;282(3):1465-72
   PubMed Web of Science ®Google Scholar
• Van Kan HJ, Groeneveld GJ, Kalmijn S, et al. Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol 2005;59(3):310-3
   PubMed Web of Science ®Google Scholar
• Van Kan HJ, van den Berg LH, Groeneveld GJ, et al. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype. Biopharm Drug Dispos 2008;29(3):139-44
   PubMed Web of Science ®Google Scholar
• De Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36(6):439-52
   PubMed Web of Science ®Google Scholar
• Fisher MB, Paine MF, Strelevitz TJ, et al. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001;33(3-4):273-97
   PubMed Web of Science ®Google Scholar
• Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002;181-182:453-6
   PubMed Web of Science ®Google Scholar
• Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003;791(1-2):337-43
   PubMed Web of Science ®Google Scholar
• Colovic, ME, Zennaro, Caccia S. Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2004;803(2):305-9
   PubMed Web of Science ®Google Scholar
• Milane A, Fernandez C, Vautier S, et al. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem 2007;103(1):164-73
   PubMed Web of Science ®Google Scholar
• Urbani, A. Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000;12(10):3567-74
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004;125(1):191-201
   PubMed Web of Science ®Google Scholar
• Noh KM, Hwang JY, Shin HC, et al. A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis 2000;7(4):375-83
   PubMed Web of Science ®Google Scholar
• Mathie A, Veale EL. Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Curr Opin Investig Drugs 2007;8(7):555-62
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Amiel JM, Coplan JD, et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005;162(12):2379-81
   PubMed Web of Science ®Google Scholar